Abstract | BACKGROUND: METHODS: Eighty-two Iranian patients with reflux esophagitis were enrolled in the study and underwent treatment with omeprazole at 40 mg daily for 4 weeks. A 2 mL sample of venous blood was obtained from each subject. CYP2C19 genetic polymorphisms were detected using the PCR-RFLP method. The patients were grouped into homo-extensive metabolizers and hetero-extensive metabolizers based on their CYP2C19 polymorphism. The grade of esophagitis was determined via endoscopy. The symptoms score was assessed at the beginning of treatment. RESULTS: Our results showed that the rate of complete clinical response to treatment with omeprazole was 95% in the hetero-extensive metabolizers group, which was higher than in the homo-extensive metabolizers group (P<0.001). CONCLUSION:
|
Authors | Nader Zendehdel, Firouzeh Biramijamal, Arash Hossein-Nezhad, Nasrin Zendehdel, Hamidreza Sarie, Masoud Doughaiemoghaddam, Akram Pourshams |
Journal | Archives of Iranian medicine
(Arch Iran Med)
Vol. 13
Issue 5
Pg. 406-12
(Sep 2010)
ISSN: 1735-3947 [Electronic] Iran |
PMID | 20804307
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Aryl Hydrocarbon Hydroxylases
- CYP2C19 protein, human
- Cytochrome P-450 CYP2C19
- Omeprazole
|
Topics |
- Adolescent
- Adult
- Aged
- Alleles
- Anti-Ulcer Agents
(therapeutic use)
- Aryl Hydrocarbon Hydroxylases
(genetics)
- Cytochrome P-450 CYP2C19
- Esophagitis, Peptic
(drug therapy, etiology, genetics)
- Esophagoscopy
- Female
- Gastroesophageal Reflux
(complications, drug therapy, genetics)
- Genotype
- Humans
- Iran
- Male
- Middle Aged
- Multivariate Analysis
- Omeprazole
(therapeutic use)
- Polymorphism, Genetic
- Proton Pump Inhibitors
(therapeutic use)
- Treatment Outcome
- Young Adult
|